Fig. 3.

Anti-SARS-CoV-2 receptor-binding domain (RBD) responses over time in participants who received two doses of study intervention. Box plots and individual plots of anti-SARS-CoV-2 RBD antibody titers over time in participants who received AZD1222 or placebo (Days 1 and 29) and were not censored at the time of study visits, determined by Meso Scale Discovery serological assay. The pooled placebo arm includes all participants who received two doses of placebo; participants who received two doses of AZD1222 are stratified by age. The bottom and top edges of the box indicate the first and third quartiles [the difference is the IQR], the line is the median, and the diamond mark is the geometric mean. The whiskers that extend from the box indicate the minimum and maximum within the range of 1.5 × IQR from the box. Box plots are created using log-transformed values. Titer values measured as below the LLoQ (204 AU/mL) are imputed to a value that is half of the LLoQ. Titer values measured as above the ULoQ (2,000,000 AU/mL) are imputed at the ULoQ value. Abbreviations: AU/mL = arbitrary units per milliliter, IQR = interquartile range, LLoQ = lower limit of quantification, RBD = receptor-binding domain, SARS-CoV-2 = severe acute respiratory syndrome-coronavirus 2, ULoQ = upper limit of quantification.